CKDXF — Opthea Ltd
—
OTC ·
Health Care ·
Biotechnology ·
CIK 1815620 ·
Australia
Last close
$0.01
Market Cap
$13.68M
52W High
$0.44
52W Low
$0.01
ADV30
0
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2024 | — | — | — | — | 145,770,000 | 131,916,000 | 314,475,000 |
| Sep 2024 | — | — | — | — | — | — | — |
Balance + Analyst (yfinance extras)
Retained Earnings
$-711,622,000
Inventory
—
Receivables
$7,984,000
ST Investments
—
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,000
EBITDA
$-11,937,000
Free Cash Flow
$-16,207,750
Enterprise Value
$-16,341,218
Total Cash
$30,021,000
Total Debt
$0
Shares Out
1,367,978,173
Trailing EPS
$0.18
Book Value
$0.02
ROE
—
ROA
-12.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 1,000 | -11,947,000 | 330,445,000 | 31,932,000 | 2,317,000 | 29,615,000 | — |
| Jun 2025 | 39,000 | -236,443,000 | -251,146,000 | 86,700,000 | 393,613,000 | -306,913,000 | — |
| Jun 2024 | 187,014 | -287,016,735 | -329,506,259 | 282,452,103 | 395,872,202 | -113,420,099 | -161,015,354 |
| Jun 2023 | 163,159 | -226,647,268 | -215,310,750 | 149,020,400 | 157,862,972 | -8,842,572 | -120,608,379 |
| Jun 2022 | — | — | — | — | — | — | -71,334,952 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ZIVO | Zivo Bioscience, Inc. | $13.91M | $3.30 | — |
| PASG | Passage BIO, Inc. | $15.04M | $4.68 | — |
| INAB | IN8BIO, INC. | $12.22M | $1.24 | — |
| PLUR | Pluri Inc. | $11.97M | $0.97 | — |
| INTS | INTENSITY THERAPEUTICS, INC. | $11.92M | $3.65 | — |
News headlines (Yahoo Finance, 1h cache)
Recent Insider Activity
No insider activity indexed for this ticker.